Technologies search results
12 Results for ''
-
Pancreatitis Tx: An Engineered Protein Treatment for Pancreatitis
First disease-modifying therapy that can be systemically applied to safely and effectively treat patients with different forms of pancreatitis. -
Human Ovarian Organoids to Improve Women’s Health
Gameto is using the Wyss Institute’s fully human ovarian organoid technology to solve the global problem of rising infertility by making IVF safer, cheaper, and more accessible. -
Metabolically Labeled CAR-T Cells Against Cancer
Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
DoriVac: Boosting Antigen-specific Immune Responses with DNA Origami-Based Vaccines
Personalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens. -
CogniXense for Rare Disease Drug Discovery
Unravel Biosciences has licensed a Wyss drug discovery platform technology to identify and create drugs to treat complex central nervous system disorders, starting with Rett syndrome. -
CircaVent: A Drug Discovery Platform for Mental Health Conditions
CircaVent is a novel drug discovery platform that combines predictive algorithms, high-throughput preclinical models, and human organoids to identify and test drugs that could treat mental health conditions like bipolar disorder. -
PhonoGraftTM: Biomimetic Hearing-restoration Technology
PhonoGraft is an eardrum-regenerating device that enables better and longer-lasting eardrum reconstruction, reducing the need for invasive surgeries and minimizing the risk of long-term hearing loss. Wyss startup Beacon Bio was acquired by Desktop Health, a healthcare business within Desktop Metal, Inc. which is further developing this technology towards commercialization with the former Wyss startup team leading the way. -
Bone Marrow-Like Scaffolds for Accelerating Immune Reconstitution
An implantable bone marrow cryogel to accelerate the full reconstitution of the immune system, including T cell immunity, in patients that received chemotherapy and a bone marrow transplant. This could provide an off-the-shelf, material-based solution for patients with severe blood disorders whose immunity is recovering only slowly after treatment. -
FcMBL: Broad-Spectrum Pathogen Capture for Infectious Disease Diagnosis and Therapy
The Problem Infectious diseases have plagued humanity for millennia, and the pathogens that infect and sicken humans are constantly evolving. Severe infections can cause sepsis, a life-threatening condition in which a patient’s immune system overreacts to the infection. The body starts to attack itself, which can lead to tissue damage, organ failure, and death. Sepsis... -
Liquid-Infused Tympanostomy Tubes
The Problem Acute middle ear infections affect more than 700 million people each year, with children often experiencing the most recurrent and severe symptoms. By the age of three, 25-40% of children have had at least three episodes of acute middle ear infection, which is commonly accompanied by excess fluids accumulating behind the tympanic membrane... -
CogniXense: A Platform for Rapid Drug Repurposing
CogniXense is a target-agnostic drug discovery platform that enables the repurposing of drugs for rare genetic diseases in record time. By combining human data-based computational drug prediction with on-demand animal model development, we can mimic the diversity of symptoms of patient populations and begin drug screening on new diseases within a month. -
Human Organs-on-Chips
Organ Chips are microfluidic devices lined with living human cells for drug development, disease modeling, and personalized medicine. Launched in 2014, Wyss startup Emulate, Inc., is leveraging the Wyss Institute’s Organ Chip technology to mimic human organs in vitro, enabling faster, better, and cheaper drug development and insights into human health.